COUR’s breakthrough nanoparticle platform harnesses the immune system’s own learning power to induce tolerance to specific problematic antigens, while preserving all immune functionality.
Upon infusion, COUR nanoparticles bind to immune cells called monocytes. The particles surface is functionalized to enhance uptake, ensuring optimal targeted delivery.
These cells then travel to the spleen and liver, where they undergo apoptosis. There, the disease-specific antigens encapsulated within the particles are released.
The resulting debris is consumed by antigen presenting cells, which present the disease-specific antigens along with negative co-stimulating factors to the adaptive immune system.
Adaptive immune T-cells interact with the antigen-presenting cells, and in the absence of inflammatory signals they “perceive” the antigen as self.
These T-cells respond by undergoing deletion or anergy…
or by inducing a T regulatory response.
T regulatory cells then migrate to sites of disease, where they continually down regulate the immune response in the presence of the disease specific antigen.
By harnessing the immune system’s built-in learning and regulatory pathways, COUR nanoparticle technology can reprogram the immune system - providing clinicians with a breakthrough approach to treating autoimmune disease.
Cour Nanoparticle Platform
For autoimmune and allergic conditions
COUR’s approach to immune tolerance is based on decades of research from the Stephen D. Miller Lab at Northwestern University. Dr. Miller uncovered the underlying mechanisms of immune tolerance induction and defined a therapeutic approach applicable to a wide range of immune-mediated diseases. Recent human clinical studies of COUR’s lead program, CNP-101, validate this approach.
The nanoparticle surface is functionalized to direct and enhance immune uptake by the mononuclear phagocyte system. The interior core is loaded with disease-specific antigen or allergen for treatment of potentially any autoimmune or allergic condition.
COUR’s nanoparticle platform proactively reprograms the immune system with new instructions that the antigen or allergen is “self,” and the immune response is to be tolerogenic, not inflammatory. This results in targeted reduction of disease specific T cell responses, while leaving the remainder of the immune system intact.
COUR’s nanoparticle therapies deliver disease-specific antigen or allergen to antigen-presenting cells (APCs) in the spleen and liver via natural, non-inflammatory, phagocytic pathways. The APCs engage antigen or allergen specific T cells, which are then deleted, rendered inactive (anergic) or converted to T regulatory cells.